Alnylam Errs on Nasdaq Index Listing; Rival Sirna Joins Index Simultaneously | GenomeWeb

Alnylam Pharmaceuticals jumped the gun last week when it said it has been added to the Nasdaq Biotechnology Index. In fact, the company joined the index one week after it said it had, and therefore was not the first RNAi company to claim inclusion on the listing.

Alnylam, in fact, joined the NBI on Monday, Nov. 21 — the same day as its close rival Sirna Therapeutics was added to the index.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.